Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Substituted tetrahydroisoquinolines as anti-mitotic drug in triple negative breast cancer

Substituted tetrahydroisoquinolines as anti-mitotic drug in triple negative breast cancer

US Patent 11839609 · Granted Dec 12, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agents2020
Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment 2020
Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment 2020
Inducing CNS neurite outgrowth with Momordica cochinchinensis extract2020
Inducing CNS neurite outgrowth with Momordica cochinchinensis extract2020
N-substituted tetrahydroisoquinoline benzamides/benzene sulfonamides as anti-can2014
N-substituted tetrahydroisoquinoline benzamides/benzene sulfonamides as anti-can2014
Herbal composition and method of use for the treatment of cancer2014
Herbal composition and method of use for the treatment of cancer2014
N-aminotetrahydroisoquinolines as anti-cancer agents2013
N-aminotetrahydroisoquinolines as anti-cancer agents2013
N-aminopyrrolylmethyltetrahydropyridines as anti-cancer agents2013